Patent 10493148 was granted and assigned to Eli Lilly and Company on December, 2019 by the United States Patent and Trademark Office.
The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.